10月31日，康弘药业获德邦证券买入评级，近一个月康弘药业获得4份研报关注。
研报预计康弘药业2023-2025年归母净利润分别为10.0/12.2/14.6亿元，同比增长12.0%/21.0%/20.2%。研报认为，康弘药业业绩超预期，康柏西普持续放量。公司业绩超预期，康柏西普未来市场潜力仍然有较大增长空间，依然为公司重磅品种，后续有望持续贡献业绩增量。盈利能力改善，期待新品后续兑现。
风险提示：核心产品销售不及预期的风险；集采或医保降价的风险；研发进度不及预期的风险。
- Headlines
- 康弘药业获德邦证券买入评级，预测2023年归母净利润为10.0亿元
康弘药业获德邦证券买入评级，预测2023年归母净利润为10.0亿元
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Hot News
Updated
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.